Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluzone (2006-2007)
NCT00389532Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2006
- Primary completion
- Apr 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Fluzone Trivalent in influenza (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of Participants With Solicited Injection Site or Systemic Reaction(s) After Fluzone® Vaccination and Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition Antibodies Pre-vaccination and Post-vaccination at 21 days. Started Oct 2006; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00389532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389532.